Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts

Bisphosphonates, therapeutic reagents against tumoral bone diseases (Paget's disease or osteoporosis), are potent inhibitors of bone resorption. The mechanisms by which they directly act on mature osteoclasts remain unclear. Using a recently developed technique for isolation of highly purified...

Full description

Saved in:
Bibliographic Details
Published in:Calcified tissue international 1999-03, Vol.64 (3), p.219-223
Main Authors: Hiroi-Furuya, E, Kameda, T, Hiura, K, Mano, H, Miyazawa, K, Nakamaru, Y, Watanabe-Mano, M, Okuda, N, Shimada, J, Yamamoto, Y, Hakeda, Y, Kumegawa, M
Format: Article
Language:English
Subjects:
Actins - drug effects
Actins - ultrastructure
Animals
Animals, Newborn
Apoptosis - drug effects
Bone Resorption - drug therapy
Cell Separation - methods
Cells, Cultured
Dentin - drug effects
Etidronic Acid - pharmacology
Microscopy, Fluorescence
Microtubules - drug effects
Microtubules - ultrastructure
Osteoclasts - drug effects
Osteoclasts - physiology
Osteoclasts - ultrastructure
Rabbits
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bisphosphonates, therapeutic reagents against tumoral bone diseases (Paget's disease or osteoporosis), are potent inhibitors of bone resorption. The mechanisms by which they directly act on mature osteoclasts remain unclear. Using a recently developed technique for isolation of highly purified mammalian mature osteoclasts, we demonstrated that etidronate [ethane-1-hydroxy-1,1-diphosphonate (EHDP), 1-hydroxy-1,1-ethylidenebisphosphonate], inhibited directly osteoclastic bone-resorbing activity by pit assay. In addition, EHDP also directly induced apoptosis and disrupted actin rings in osteoclasts. The data support previous data on non-purified osteoclasts and results in vivo.
ISSN:0171-967X
1432-0827
DOI:10.1007/s002239900606